Tuberculosis (TB) is a preventable and curable disease, and yet it continues to affect over 10 million people worldwide every year. Without immediate action to end TB, the human and economic toll will continue to climb.
The TB epidemic is perpetuated by inadequate funding and insufficient political will. Investing in research and development to improve the tools available for the prevention, diagnosis, and treatment of TB is a critical pathway to eradicating this disease. The current reliance on outdated tools is unacceptable – people affected by TB deserve access to modern, effective solutions.
This report co-authored with Results UK presents the case for meeting the financial targets for TB research and development to ensure all people can benefit from scientific progress. Investing in TB research offers not only financial returns but also strengthens health systems, builds research capacity, improves health outcomes, and enhances global health security for all.
